Notably, recent evidence has indicated that statins lead to better clinical outcomes in malignant pleural mesothelioma (MPM) and advanced NSCLC patients treated with the immune checkpoint inhibitor, nivolumab, a programmed cell death protein 1 (PD-1)-targeting monoclonal antibody, indicating that statins are also available for combination cancer therapy with immune checkpoint inhibitors [18,19]. Here, PDCD1 is linked to malignant pleural mesothelioma.